Clinical Trials Logo

Corneal Crosslinking clinical trials

View clinical trials related to Corneal Crosslinking.

Filter by:
  • None
  • Page 1

NCT ID: NCT04668924 Active, not recruiting - Keratoconus Clinical Trials

Epi-on PiXL for the Treatment of Progressive Keratoconus.

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and postoperative ocular discomfort by individually customized Photorefractive intrastromal crosslinking (PiXL) without epithelium debridement in high oxygen environment (Epi-on) for progressive Keratoconus.

NCT ID: NCT03990506 Completed - Keratoconus Clinical Trials

Photorefractive Intrastromal Crosslinking (PiXL) for the Treatment of Progressive Keratoconus

Start date: April 2, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and postoperative ocular discomfort by comparing individually customized Photorefractive intrastromal crosslinking (PiXL) for progressive Keratoconus. The study compares two different protocols, PiXL with corneal epithelium debridement (Epi-off) and PiXL without epithelium debridement in high oxygen environment (Epi-on), with the hypothesis that Epi-on gives less postoperative ocular discomfort.

NCT ID: NCT03987880 Completed - Myopia Clinical Trials

Photorefractive Intrastromal Corneal Crosslinking as a Treatment for Low Grade Myopia

Start date: January 22, 2018
Phase: N/A
Study type: Interventional

To assess the improvement in refractive error and the corneal endothelial safety with a customized corneal crosslinking treatment regimen for low grade myopia. The study compares two treatment protocols, a 4.0-mm central ring-shaped zone with a 3.5-mm central ring-shaped zone in high oxygen environment without corneal epithelial debridement.

NCT ID: NCT03197272 Completed - Myopia Clinical Trials

Advanced Cross Linking for Low-grade Myopia

PiXLO2
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

To evaluate the improvement in myopic refractive error and the corneal endothelial safety with a corneal crosslinking treatment regimen for mild myopia. The treatment involves a 4-mm central treatment zone in high oxygen environment without corneal epithelial debridement.